What is Leerink Partnrs’ Forecast for Insulet Q4 Earnings?

Insulet Co. (NASDAQ:PODD) – Equities researchers at Leerink Partnrs lowered their Q4 2024 EPS estimates for Insulet in a research note issued on Monday, November 25th. Leerink Partnrs analyst M. Kratky now forecasts that the medical instruments supplier will post earnings of $0.97 per share for the quarter, down from their prior estimate of $0.99. The consensus estimate for Insulet’s current full-year earnings is $3.22 per share. Leerink Partnrs also issued estimates for Insulet’s Q2 2025 earnings at $0.87 EPS, Q3 2025 earnings at $1.14 EPS, Q4 2025 earnings at $1.20 EPS, FY2025 earnings at $3.89 EPS, FY2026 earnings at $5.21 EPS and FY2027 earnings at $6.49 EPS.

Several other analysts have also recently commented on the company. Sanford C. Bernstein started coverage on Insulet in a report on Wednesday, November 6th. They issued an “outperform” rating and a $300.00 target price on the stock. Piper Sandler increased their price objective on shares of Insulet from $230.00 to $285.00 and gave the stock an “overweight” rating in a research report on Tuesday, September 17th. Canaccord Genuity Group lifted their target price on shares of Insulet from $236.00 to $269.00 and gave the stock a “buy” rating in a research note on Wednesday, September 25th. UBS Group upped their price target on shares of Insulet from $211.00 to $223.00 and gave the company a “neutral” rating in a research report on Friday, August 9th. Finally, Morgan Stanley lifted their price objective on Insulet from $234.00 to $317.00 and gave the stock an “overweight” rating in a research report on Monday, November 11th. Three equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. Based on data from MarketBeat.com, Insulet presently has an average rating of “Moderate Buy” and a consensus target price of $253.27.

Insulet Trading Up 0.2 %

Shares of PODD stock opened at $266.92 on Tuesday. Insulet has a 1-year low of $160.19 and a 1-year high of $279.40. The company has a current ratio of 3.68, a quick ratio of 2.80 and a debt-to-equity ratio of 1.21. The stock has a market cap of $18.72 billion, a price-to-earnings ratio of 45.70, a PEG ratio of 4.08 and a beta of 1.22. The stock has a 50-day moving average of $242.59 and a 200-day moving average of $212.36.

Institutional Investors Weigh In On Insulet

A number of hedge funds have recently added to or reduced their stakes in the company. Blue Trust Inc. lifted its holdings in shares of Insulet by 84.1% in the 3rd quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier’s stock worth $30,000 after purchasing an additional 58 shares in the last quarter. Venturi Wealth Management LLC grew its holdings in shares of Insulet by 633.3% during the third quarter. Venturi Wealth Management LLC now owns 154 shares of the medical instruments supplier’s stock valued at $36,000 after buying an additional 133 shares during the last quarter. International Assets Investment Management LLC acquired a new stake in shares of Insulet in the 2nd quarter worth about $32,000. UMB Bank n.a. lifted its position in Insulet by 81.0% in the 2nd quarter. UMB Bank n.a. now owns 181 shares of the medical instruments supplier’s stock valued at $37,000 after acquiring an additional 81 shares in the last quarter. Finally, TD Private Client Wealth LLC boosted its stake in Insulet by 32.6% during the 3rd quarter. TD Private Client Wealth LLC now owns 228 shares of the medical instruments supplier’s stock valued at $53,000 after purchasing an additional 56 shares during the last quarter.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.